<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36879504</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1708-8267</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of investigative medicine : the official publication of the American Federation for Clinical Research</Title><ISOAbbreviation>J Investig Med</ISOAbbreviation></Journal><ArticleTitle>The role of immune activation and antigen persistence in acute and long COVID.</ArticleTitle><Pagination><StartPage>545</StartPage><EndPage>562</EndPage><MedlinePgn>545-562</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/10815589231158041</ELocationID><Abstract><AbstractText>In late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) triggered the global coronavirus disease 2019 (COVID-19) pandemic. Although most infections cause a self-limited syndrome comparable to other upper respiratory viral pathogens, a portion of individuals develop severe illness leading to substantial morbidity and mortality. Furthermore, an estimated 10%-20% of SARS-CoV-2 infections are followed by post-acute sequelae of COVID-19 (PASC), or long COVID. Long COVID is associated with a wide variety of clinical manifestations including cardiopulmonary complications, persistent fatigue, and neurocognitive dysfunction. Severe acute COVID-19 is associated with hyperactivation and increased inflammation, which may be an underlying cause of long COVID in a subset of individuals. However, the immunologic mechanisms driving long COVID development are still under investigation. Early in the pandemic, our group and others observed immune dysregulation persisted into convalescence after acute COVID-19. We subsequently observed persistent immune dysregulation in a cohort of individuals experiencing long COVID. We demonstrated increased SARS-CoV-2-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-cell responses and antibody affinity in patients experiencing long COVID symptoms. These data suggest a portion of long COVID symptoms may be due to chronic immune activation and the presence of persistent SARS-CoV-2 antigen. This review summarizes the COVID-19 literature to date detailing acute COVID-19 and convalescence and how these observations relate to the development of long COVID. In addition, we discuss recent findings in support of persistent antigen and the evidence that this phenomenon contributes to local and systemic inflammation and the heterogeneous nature of clinical manifestations seen in long COVID.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Opsteen</LastName><ForeName>Skye</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Files</LastName><ForeName>Jacob K</ForeName><Initials>JK</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fram</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erdmann</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K08 AI129705</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Investig Med</MedlineTA><NlmUniqueID>9501229</NlmUniqueID><ISSNLinking>1081-5589</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="Y">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003289" MajorTopicYN="N">Convalescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword></KeywordList><CoiStatement>The author(s) declared the following potential conflicts of interest with respect to the
research, authorship, and/or publication of this article: Author NE&#x2014;intellectual property
(IP), &#x201c;Human neutralizing antibodies against SARS-CoV-2/COVID-19&#x201d; licensed to the
Plantform Corp.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>7</Day><Hour>1</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36879504</ArticleId><ArticleId IdType="pmc">PMC9996119</ArticleId><ArticleId IdType="doi">10.1177/10815589231158041</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dong E, Du H, Gardner L.An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020; 20: 533&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159018</ArticleId><ArticleId IdType="pubmed">32087114</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahrenfeldt LJ, Nielsen CR, M&#xf6;ller S, et al.. Burden and prevalence of risk factors for severe COVID-19 disease in the ageing European population&#x2013;A SHARE-based analysis. Z Gesundh Wiss 2022; 30: 2081&#x2013;2090.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8036158</ArticleId><ArticleId IdType="pubmed">33868899</ArticleId></ArticleIdList></Reference><Reference><Citation>Anesi GL, Halpern SD, Delgado MK.Covid-19 related hospital admissions in the United States: needs and outcomes. BMJ 2020; 369: m2082.</Citation><ArticleIdList><ArticleId IdType="pubmed">32461214</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohn MK, Hall A, Sepiashvili L, et al.. Pathophysiology of COVID-19: mechanisms underlying disease severity and progression. Physiology (Bethesda) 2020; 35: 288&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7426542</ArticleId><ArticleId IdType="pubmed">32783610</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N, Zhou M, Dong X, et al.. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaeuffer C, Le Hyaric C, Fabacher T, et al.. Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020. Euro Surveill 2020; 25: 2000895.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7716399</ArticleId><ArticleId IdType="pubmed">33272355</ArticleId></ArticleIdList></Reference><Reference><Citation>McPadden J, Warner F, Young HP, et al.. Clinical characteristics and outcomes for 7,995 patients with SARS-CoV-2 infection. PLoS One 2021; 16: e0243291.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8011821</ArticleId><ArticleId IdType="pubmed">33788846</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendiola-Pastrana IR, Lopez-Ortiz E, Rio de la Loza-Zamora JG, et al.. SARS-CoV-2 variants and clinical outcomes: a systematic review. Life (Basel) 2022; 12: 170.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8879159</ArticleId><ArticleId IdType="pubmed">35207458</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, et al.. Factors associated with COVID-19-related death using OpenSAFELY. Nature 2020; 584: 430&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Coronavirus
disease (covid-19): Post covid-19 condition, 2021.
https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition
(accessed 22 September 2022).</Citation></Reference><Reference><Citation>Centers for Disease Control and
Prevention. Nearly one in five American adults who have had
COVID-19 still have &#x201c;long covid&#x201d;, 2022. https://www.cdc.gov/nchs/pressroom/nchs_press_releases/2022/20220622.htm
(accessed 22 September 2022).</Citation></Reference><Reference><Citation>Choutka J, Jansari V, Hornig M, et al.. Unexplained post-acute infection syndromes. Nat Med 2022; 28: 911&#x2013;923.</Citation><ArticleIdList><ArticleId IdType="pubmed">35585196</ArticleId></ArticleIdList></Reference><Reference><Citation>Li F, Li W, Farzan M, et al.. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005; 309: 1864&#x2013;1868.</Citation><ArticleIdList><ArticleId IdType="pubmed">16166518</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang N, Shi X, Jiang L, et al.. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 2013; 23: 986&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3731569</ArticleId><ArticleId IdType="pubmed">23835475</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R, Zhao X, Li J, et al.. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020; 395: 565&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang XL, Wang XG, et al.. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020; 579: 270&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Donoghue M, Hsieh F, Baronas E, et al.. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1&#x2013;E9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10969042</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y, He L, Zhang Q, et al.. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol 2004; 203: 622&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167761</ArticleId><ArticleId IdType="pubmed">15141376</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamming I, Timens W, Bulthuis ML, et al.. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol 2004; 203: 631&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7167720</ArticleId><ArticleId IdType="pubmed">15141377</ArticleId></ArticleIdList></Reference><Reference><Citation>Li MY, Li L, Zhang Y, et al.. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty 2020; 9: 45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186534</ArticleId><ArticleId IdType="pubmed">32345362</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni W, Yang X, Yang D, et al.. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit Care 2020; 24: 422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7356137</ArticleId><ArticleId IdType="pubmed">32660650</ArticleId></ArticleIdList></Reference><Reference><Citation>Salamanna F, Maglio M, Landini MP, et al.. Body localization of ACE-2: on the trail of the keyhole of SARS-CoV-2. Front Med (Lausanne) 2020; 7: 594495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7744810</ArticleId><ArticleId IdType="pubmed">33344479</ArticleId></ArticleIdList></Reference><Reference><Citation>Tipnis SR, Hooper NM, Hyde R, et al.. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238&#x2013;33243.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924499</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Li HB, Lyu JR, et al.. Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. Int J Infect Dis 2020; 96: 19&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165079</ArticleId><ArticleId IdType="pubmed">32311451</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou X, Chen K, Zou J, et al.. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med 2020; 14: 185&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7088738</ArticleId><ArticleId IdType="pubmed">32170560</ArticleId></ArticleIdList></Reference><Reference><Citation>Peiris JS, Yuen KY, Osterhaus AD, et al.. The severe acute respiratory syndrome. N Engl J Med 2003; 349: 2431&#x2013;2441.</Citation><ArticleIdList><ArticleId IdType="pubmed">14681510</ArticleId></ArticleIdList></Reference><Reference><Citation>Zumla A, Hui DS, Perlman S.Middle east respiratory syndrome. Lancet 2015; 386: 995&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4721578</ArticleId><ArticleId IdType="pubmed">26049252</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen E, Koopmans M, Go U, et al.. Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics. Lancet Infect Dis 2020; 20: e238&#x2013;e244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7333991</ArticleId><ArticleId IdType="pubmed">32628905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed H, Patel K, Greenwood DC, et al.. Long-term clinical outcomes in survivors of severe acute respiratory syndrome and middle east respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis. J Rehabil Med 2020; 52: jrm00063.</Citation><ArticleIdList><ArticleId IdType="pubmed">32449782</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SH, Shin HS, Park HY, et al.. Depression as a mediator of chronic fatigue and post-traumatic stress symptoms in middle east respiratory syndrome survivors. Psychiatry Investig 2019; 16: 59&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6354037</ArticleId><ArticleId IdType="pubmed">30605995</ArticleId></ArticleIdList></Reference><Reference><Citation>Files JK, Boppana S, Perez MD, et al.. Sustained cellular immune dysregulation in individuals recovering from SARS-CoV-2 infection. J Clin Invest 2021; 131: e140491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7773371</ArticleId><ArticleId IdType="pubmed">33119547</ArticleId></ArticleIdList></Reference><Reference><Citation>Files JK, Sarkar S, Fram TR, et al.. Duration of post-COVID-19 symptoms is associated with sustained SARS-CoV-2-specific immune responses. JCI Insight 2021; 6: e151544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8410022</ArticleId><ArticleId IdType="pubmed">34143754</ArticleId></ArticleIdList></Reference><Reference><Citation>Castanares-Zapatero D, Chalon P, Kohn L, et al.. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med 2022; 54: 1473&#x2013;1487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9132392</ArticleId><ArticleId IdType="pubmed">35594336</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung CCL, Goh D, Lim X, et al.. Residual SARS-CoV-2 viral antigens detected in GI and hepatic tissues from five recovered patients with COVID-19. Gut 2022; 71: 226&#x2013;229.</Citation><ArticleIdList><ArticleId IdType="pubmed">34083386</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J, Wood J, Jaycox J, et al.. Distinguishing features of long COVID identified through immune profiling. medRxiv 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Park SK, Lee CW, Park DI, et al.. Detection of SARS-CoV-2 in fecal samples from patients with asymptomatic and mild COVID-19 in Korea. Clin Gastroenterol Hepatol 2021; 19: 1387.e2&#x2013;1394.e2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7286243</ArticleId><ArticleId IdType="pubmed">32534042</ArticleId></ArticleIdList></Reference><Reference><Citation>Proal AD, VanElzakker MB.Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front Microbiol 2021; 12: 698169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260991</ArticleId><ArticleId IdType="pubmed">34248921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ram-Mohan N, Kim D, Rogers AJ, et al.. Association between SARS-CoV-2 RNAemia and post-acute sequelae of COVID-19. medRxiv. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8802799</ArticleId><ArticleId IdType="pubmed">35111870</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG, et al.. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell 2022; 185: 881.e20&#x2013;895.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Swank Z, Senussi Y, Manickas-Hill Z, et al.. Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae. Clin Infect Dis 2023; 76: e487&#x2013;e490.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10169416</ArticleId><ArticleId IdType="pubmed">36052466</ArticleId></ArticleIdList></Reference><Reference><Citation>Vibholm LK, Nielsen SSF, Pahus MH, et al.. SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responses. EBioMedicine 2021; 64: 103230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7847186</ArticleId><ArticleId IdType="pubmed">33530000</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson BK, Francisco EB, Yogendra R, et al.. Persistence of SARS CoV-2 S1 protein in CD16+ monocytes in post-acute sequelae of COVID-19 (PASC) up to 15 months post-infection. Front Immunol 2021; 12: 746021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8784688</ArticleId><ArticleId IdType="pubmed">35082777</ArticleId></ArticleIdList></Reference><Reference><Citation>Merad M, Blish CA, Sallusto F, et al.. The immunology and immunopathology of COVID-19. Science 2022; 375: 1122&#x2013;1127.</Citation><ArticleIdList><ArticleId IdType="pubmed">35271343</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C, Valdes AM, Polidori L, et al.. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet 2022; 399: 1618&#x2013;1624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokes EK, Zambrano LD, Anderson KN, et al.. Coronavirus disease 2019 case surveillance - United States, January 22&#x2013;May 30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 759&#x2013;765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7302472</ArticleId><ArticleId IdType="pubmed">32555134</ArticleId></ArticleIdList></Reference><Reference><Citation>Tenforde MW, Billig Rose E, Lindsell CJ, et al.. Characteristics of adult outpatients and inpatients with COVID-19 - 11 academic medical centers, United States, March&#x2013;May 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 841&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332092</ArticleId><ArticleId IdType="pubmed">32614810</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Zheng Y, Gou X, et al.. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020; 94: 91&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7194638</ArticleId><ArticleId IdType="pubmed">32173574</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Wu D, Guo W, et al.. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130: 2620&#x2013;2629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190990</ArticleId><ArticleId IdType="pubmed">32217835</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al.. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, et al.. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA 2020; 323: 2052&#x2013;2059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C, Lei Q, Li W, et al.. Epidemiological and clinical characteristics of 1663 hospitalized patients infected with COVID-19 in Wuhan, China: a single-center experience. J Infect Public Health 2020; 13: 1202&#x2013;1209.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7367029</ArticleId><ArticleId IdType="pubmed">32718894</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C, Chen X, Cai Y, et al.. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180: 934&#x2013;943.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al.. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Andeweg SP, Vennema H, Veldhuijzen I, et al.. Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated individuals. Sci Transl Med 2023; 15: eabn4338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9580257</ArticleId><ArticleId IdType="pubmed">35862508</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanca D, Nicolosi S, Bandera A, et al.. Comparison between the first and second COVID-19 waves in internal medicine wards in Milan, Italy: a retrospective observational study. Intern Emerg Med 2022; 17: 2219&#x2013;2228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9377666</ArticleId><ArticleId IdType="pubmed">35970982</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutta A.COVID-19 waves: variant dynamics and control. Sci Rep 2022; 12: 9332.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9166180</ArticleId><ArticleId IdType="pubmed">35661125</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Shabasy RM, Nayel MA, Taher MM, et al.. Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic. Int J Biol Macromol 2022; 204: 161&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8782737</ArticleId><ArticleId IdType="pubmed">35074332</ArticleId></ArticleIdList></Reference><Reference><Citation>GeurtsvanKessel CH, Geers D, Schmitz KS, et al.. Divergent SARS-CoV-2 omicron-reactive T and B cell responses in COVID-19 vaccine recipients. Sci Immunol 2022; 7: eabo2202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8939771</ArticleId><ArticleId IdType="pubmed">35113647</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu T, Zhang M, Deng A, et al.. Comparison of omicron and delta variant infection COVID-19 cases - guangdong province, China, 2022. China CDC Wkly 2022; 4: 385&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9167612</ArticleId><ArticleId IdType="pubmed">35686204</ArticleId></ArticleIdList></Reference><Reference><Citation>Klaser K, Molteni E, Graham M, et al.. COVID-19 due to the B.1.617.2 (Delta) variant compared to B.1.1.7 (Alpha) variant of SARS-CoV-2: a prospective observational cohort study. Sci Rep 2022; 12: 10904.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240087</ArticleId><ArticleId IdType="pubmed">35764879</ArticleId></ArticleIdList></Reference><Reference><Citation>Mileto D, Micheli V, Fenizia C, et al.. Reduced neutralization of SARS-CoV-2 omicron variant by BNT162b2 vaccinees&#x2019; sera: a preliminary evaluation. Emerg Microbes Infect 2022; 11: 790&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8920392</ArticleId><ArticleId IdType="pubmed">35196967</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui S, Alhamdi HWS, Alghamdi HA.Recent chronology of COVID-19 pandemic. Front Public Health 2022; 10: 778037.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9114873</ArticleId><ArticleId IdType="pubmed">35602161</ArticleId></ArticleIdList></Reference><Reference><Citation>Vo GV, Bagyinszky E, An SSA. COVID-19 genetic variants and their potential impact in vaccine development. Microorganisms 2022; 10: 598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8954257</ArticleId><ArticleId IdType="pubmed">35336173</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M, Pujol JC, Spector TD, et al.. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet 2022; 399: 2263&#x2013;2264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Bager P, Wohlfahrt J, Bhatt S, et al.. Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study. Lancet Infect Dis 2022; 22: 967&#x2013;976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9033212</ArticleId><ArticleId IdType="pubmed">35468331</ArticleId></ArticleIdList></Reference><Reference><Citation>Iuliano AD, Brunkard JM, Boehmer TK, et al.. Trends in disease severity and health care utilization during the early omicron variant period compared with previous SARS-CoV-2 high transmission periods - United States, December 2020&#x2013;January 2022. MMWR Morb Mortal Wkly Rep 2022; 71: 146&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9351529</ArticleId><ArticleId IdType="pubmed">35085225</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhi SA, Kwatra G, Myers JE, et al.. Population immunity and Covid-19 severity with omicron variant in South Africa. N Engl J Med 2022; 386: 1314&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908853</ArticleId><ArticleId IdType="pubmed">35196424</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolter N, Jassat W, Walaza S, et al.. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet 2022; 399: 437&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8769664</ArticleId><ArticleId IdType="pubmed">35065011</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenet M, Lebreil AL, Heng L, et al.. Asymptomatic COVID-19 adult outpatients identified as significant viable SARS-CoV-2 shedders. Sci Rep 2021; 11: 20615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8523690</ArticleId><ArticleId IdType="pubmed">34663858</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Kim T, Lee E, et al.. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the republic of Korea. JAMA Intern Med 2020; 180: 1447&#x2013;1452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7411944</ArticleId><ArticleId IdType="pubmed">32780793</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamae Y, Hayashi T, Yonezawa H, et al.. Duration of viral shedding in asymptomatic or mild cases of novel coronavirus disease 2019 (COVID-19) from a cruise ship: a single-hospital experience in Tokyo, Japan. Int J Infect Dis 2020; 97: 293&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7289725</ArticleId><ArticleId IdType="pubmed">32535295</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata T, Sakurai A, Suzuki M, et al.. Shedding of viable virus in asymptomatic SARS-CoV-2 carriers. mSphere 2021; 6: e00019&#x2013;e00021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8265619</ArticleId><ArticleId IdType="pubmed">34011679</ArticleId></ArticleIdList></Reference><Reference><Citation>Saurabh S, Kumar R, Gupta MK, et al.. Prolonged persistence of SARS-CoV-2 in the upper respiratory tract of asymptomatic infected individuals. QJM 2020; 113: 556&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337859</ArticleId><ArticleId IdType="pubmed">32609360</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YT, Shao SC, Hsu CK, et al.. Incidence of acute kidney injury in COVID-19 infection: a systematic review and meta-analysis. Crit Care 2020; 24: 346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7296284</ArticleId><ArticleId IdType="pubmed">32546191</ArticleId></ArticleIdList></Reference><Reference><Citation>Long B, Brady WJ, Koyfman A, et al.. Cardiovascular complications in COVID-19. Am J Emerg Med 2020; 38: 1504&#x2013;1507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165109</ArticleId><ArticleId IdType="pubmed">32317203</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao R, Qiu Y, He JS, et al.. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5: 667&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7217643</ArticleId><ArticleId IdType="pubmed">32405603</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi K, Zeng W, Ye M, et al.. Clinical, laboratory, and imaging features of pediatric COVID-19: a systematic review and meta-analysis. Medicine (Baltimore) 2021; 100: e25230.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8052054</ArticleId><ArticleId IdType="pubmed">33847620</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al.. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 2020; 181: 1036.e9&#x2013;1045.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7227586</ArticleId><ArticleId IdType="pubmed">32416070</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadjadj J, Yatim N, Barnabei L, et al.. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science 2020; 369: 718&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402632</ArticleId><ArticleId IdType="pubmed">32661059</ArticleId></ArticleIdList></Reference><Reference><Citation>Lucas C, Wong P, Klein J, et al.. Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature 2020; 584: 463&#x2013;469.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7477538</ArticleId><ArticleId IdType="pubmed">32717743</ArticleId></ArticleIdList></Reference><Reference><Citation>Sposito B, Broggi A, Pandolfi L, et al.. The interferon landscape along the respiratory tract impacts the severity of COVID-19. Cell 2021; 184: 4953.e16&#x2013;4968.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8373821</ArticleId><ArticleId IdType="pubmed">34492226</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilk AJ, Rustagi A, Zhao NQ, et al.. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat Med 2020; 26: 1070&#x2013;1076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7382903</ArticleId><ArticleId IdType="pubmed">32514174</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai Q, Huang D, Ou P, et al.. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy 2020; 75: 1742&#x2013;1752.</Citation><ArticleIdList><ArticleId IdType="pubmed">32239761</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Y, Li T, Han M, et al.. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 2020; 92: 791&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228247</ArticleId><ArticleId IdType="pubmed">32181911</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold T, Jurinovic V, Arnreich C, et al.. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol 2020; 146: 128.e4&#x2013;136.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233239</ArticleId><ArticleId IdType="pubmed">32425269</ArticleId></ArticleIdList></Reference><Reference><Citation>Leisman DE, Ronner L, Pinotti R, et al.. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med 2020; 8: 1233&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7567529</ArticleId><ArticleId IdType="pubmed">33075298</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Li S, Liu J, et al.. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 2020; 55: 102763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165294</ArticleId><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu T, Zhang J, Yang Y, et al.. The role of interleukin-6 in monitoring severe case of coronavirus disease 2019. EMBO Mol Med 2020; 12: e12421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7280589</ArticleId><ArticleId IdType="pubmed">32428990</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q, Yang K, Wang W, et al.. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020; 46: 846&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7080116</ArticleId><ArticleId IdType="pubmed">32125452</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan M, Liu Y, Zhou R, et al.. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology 2020; 160: 261&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283723</ArticleId><ArticleId IdType="pubmed">32460357</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z, Yang B, Li Q, et al.. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 2020; 71: 769&#x2013;777.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184452</ArticleId><ArticleId IdType="pubmed">32176772</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Shen C, Li J, et al.. Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19. J Allergy Clin Immunol 2020; 146: 119.e4&#x2013;127.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7189843</ArticleId><ArticleId IdType="pubmed">32360286</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang B, Zhou X, Zhu C, et al.. Immune phenotyping based on the neutrophil-to-lymphocyte ratio and IgG level predicts disease severity and outcome for patients with COVID-19. Front Mol Biosci 2020; 7: 157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7350507</ArticleId><ArticleId IdType="pubmed">32719810</ArticleId></ArticleIdList></Reference><Reference><Citation>Diao B, Wang C, Tan Y, et al.. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol 2020; 11: 827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7205903</ArticleId><ArticleId IdType="pubmed">32425950</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathew D, Giles JR, Baxter AE, et al.. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science 2020; 369: eabc8511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7402624</ArticleId><ArticleId IdType="pubmed">32669297</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Balushi A, AlShekaili J, Al Kindi M, et al.. Immunological predictors of disease severity in patients with COVID-19. Int J Infect Dis 2021; 110: 83&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8245310</ArticleId><ArticleId IdType="pubmed">34216735</ArticleId></ArticleIdList></Reference><Reference><Citation>Song JW, Zhang C, Fan X, et al.. Immunological and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun 2020; 11: 3410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7343781</ArticleId><ArticleId IdType="pubmed">32641700</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei LL, Wang WJ, Chen DX, et al.. Dysregulation of the immune response affects the outcome of critical COVID-19 patients. J Med Virol 2020; 92: 2768&#x2013;2776.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323247</ArticleId><ArticleId IdType="pubmed">32543740</ArticleId></ArticleIdList></Reference><Reference><Citation>Youngs J, Provine NM, Lim N, et al.. Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. PLoS Pathog 2021; 17: e1009804.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8445447</ArticleId><ArticleId IdType="pubmed">34529726</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng HY, Zhang M, Yang CX, et al.. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell Mol Immunol 2020; 17: 541&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7091621</ArticleId><ArticleId IdType="pubmed">32203186</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M, Gao Y, Wang G, et al.. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 2020; 17: 533&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7091858</ArticleId><ArticleId IdType="pubmed">32203188</ArticleId></ArticleIdList></Reference><Reference><Citation>Carsetti R, Zaffina S, Piano Mortari E, et al.. Different innate and adaptive immune responses to SARS-CoV-2 infection of asymptomatic, mild, and severe cases. Front Immunol 2020; 11: 610300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7772470</ArticleId><ArticleId IdType="pubmed">33391280</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni A, Maggi L, Capone M, et al.. Cell-mediated and humoral adaptive immune responses to SARS-CoV-2 are lower in asymptomatic than symptomatic COVID-19 patients. Eur J Immunol 2020; 50: 2013&#x2013;2024.</Citation><ArticleIdList><ArticleId IdType="pubmed">33080068</ArticleId></ArticleIdList></Reference><Reference><Citation>Oja AE, Saris A, Ghandour CA, et al.. Divergent SARS-CoV-2-specific T- and B-cell responses in severe but not mild COVID-19 patients. Eur J Immunol 2020; 50: 1998&#x2013;2012.</Citation><ArticleIdList><ArticleId IdType="pubmed">33073359</ArticleId></ArticleIdList></Reference><Reference><Citation>Grau-Exposito J, Sanchez-Gaona N, Massana N, et al.. Peripheral and lung resident memory T cell responses against SARS-CoV-2. Nat Commun 2021; 12: 3010.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8140108</ArticleId><ArticleId IdType="pubmed">34021148</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliviero B, Varchetta S, Mele D, et al.. Expansion of atypical memory B cells is a prominent feature of COVID-19. Cell Mol Immunol 2020; 17: 1101&#x2013;1103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7463104</ArticleId><ArticleId IdType="pubmed">32879471</ArticleId></ArticleIdList></Reference><Reference><Citation>Pusnik J, Richter E, Schulte B, et al.. Memory B cells targeting SARS-CoV-2 spike protein and their dependence on CD4(+) T cell help. Cell Rep 2021; 35: 109320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8192958</ArticleId><ArticleId IdType="pubmed">34146478</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuwa HA, Shaw TN, Knight SB, et al.. Alterations in T and B cell function persist in convalescent COVID-19 patients. Med (N Y) 2021; 2: 720.e4&#x2013;735.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8011689</ArticleId><ArticleId IdType="pubmed">33821250</ArticleId></ArticleIdList></Reference><Reference><Citation>Eyre DW, Taylor D, Purver M, et al.. Effect of Covid-19 vaccination on transmission of alpha and delta variants. N Engl J Med 2022; 386: 744&#x2013;756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8757571</ArticleId><ArticleId IdType="pubmed">34986294</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall V, Foulkes S, Insalata F, et al.. Protection against SARS-CoV-2 after Covid-19 vaccination and previous infection. N Engl J Med 2022; 386: 1207&#x2013;1220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908850</ArticleId><ArticleId IdType="pubmed">35172051</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris RJ, Hall JA, Zaidi A, et al.. Effect of vaccination on household transmission of SARS-CoV-2 in England. N Engl J Med 2021; 385: 759&#x2013;760.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262621</ArticleId><ArticleId IdType="pubmed">34161702</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah ASV, Gribben C, Bishop J, et al.. Effect of vaccination on transmission of SARS-CoV-2. N Engl J Med 2021; 385: 1718&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8451182</ArticleId><ArticleId IdType="pubmed">34496200</ArticleId></ArticleIdList></Reference><Reference><Citation>Calcoen B, Callewaert N, Vandenbulcke A, et al.. High incidence of SARS-CoV-2 variant of concern breakthrough infections despite residual humoral and cellular immunity induced by BNT162b2 vaccination in healthcare workers: a long-term follow-up study in Belgium. Viruses 2022; 14: 1257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9228150</ArticleId><ArticleId IdType="pubmed">35746728</ArticleId></ArticleIdList></Reference><Reference><Citation>Favresse J, Dogne JM, Douxfils J.Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster. Clin Chem Lab Med 2022; 60: e153&#x2013;e156.</Citation><ArticleIdList><ArticleId IdType="pubmed">35452575</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohlendick B, Ciuciulkaite I, Elsner C, et al.. Individuals with weaker antibody responses after booster immunization are prone to omicron breakthrough infections. Front Immunol 2022; 13: 907343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9260040</ArticleId><ArticleId IdType="pubmed">35812411</ArticleId></ArticleIdList></Reference><Reference><Citation>Staerke NB, Reekie J, Nielsen H, et al.. Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections. Nat Commun 2022; 13: 4466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9342834</ArticleId><ArticleId IdType="pubmed">35915081</ArticleId></ArticleIdList></Reference><Reference><Citation>Tay MZ, Rouers A, Fong SW, et al.. Decreased memory B cell frequencies in COVID-19 delta variant vaccine breakthrough infection. EMBO Mol Med 2022; 14: e15227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8899913</ArticleId><ArticleId IdType="pubmed">34994081</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang SL, Mat Ripen A, Leong CT, et al.. COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia. Emerg Microbes Infect 2022; 11: 1262&#x2013;1271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9067955</ArticleId><ArticleId IdType="pubmed">35412409</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-Rivas G, Barallat J, Quirant-Sanchez B, et al.. Follow up of the humoral response in healthcare workers after the administration of two dose of the anti SARS-CoV-2 vaccines-effectiveness in delta variant breakthrough infections. Viruses 2022; 14: 1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9315723</ArticleId><ArticleId IdType="pubmed">35891366</ArticleId></ArticleIdList></Reference><Reference><Citation>Breton G, Mendoza P, Hagglof T, et al.. Persistent cellular immunity to SARS-CoV-2 Infection. bioRxiv. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7845919</ArticleId><ArticleId IdType="pubmed">33533915</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan JM, Mateus J, Kato Y, et al.. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science 2021; 371: eabf4063.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7919858</ArticleId><ArticleId IdType="pubmed">33408181</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudd PA, Remy KE.Prolonged adaptive immune activation in COVID-19: implications for maintenance of long-term immunity? J Clin Invest 2021; 131: e143928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7773393</ArticleId><ArticleId IdType="pubmed">33104057</ArticleId></ArticleIdList></Reference><Reference><Citation>Orologas-Stavrou N, Politou M, Rousakis P, et al.. Peripheral blood immune profiling of convalescent plasma donors reveals alterations in specific immune subpopulations even at 2 months post SARS-CoV-2 infection. Viruses 2020; 13: 26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7824046</ArticleId><ArticleId IdType="pubmed">33375675</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherina N, Piralla A, Du L, et al.. Persistence of SARS-CoV-2-specific B and T cell responses in convalescent COVID-19 patients 6-8 months after the infection. Med (N Y) 2021; 2: 281.e4&#x2013;295.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7874960</ArticleId><ArticleId IdType="pubmed">33589885</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen W, Su W, Tang H, et al.. Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov 2020; 6: 31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197635</ArticleId><ArticleId IdType="pubmed">32377375</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheatley AK, Juno JA, Wang JJ, et al.. Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19. Nat Commun 2021; 12: 1162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896046</ArticleId><ArticleId IdType="pubmed">33608522</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L, Dyer AH, Naughton A, et al.. Longitudinal analysis of COVID-19 patients shows age-associated T cell changes independent of ongoing Ill-health. Front Immunol 2021; 12: 676932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8138306</ArticleId><ArticleId IdType="pubmed">34025675</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardieck IN, Beyrend G, Redeker A, et al.. Cytomegalovirus infection and progressive differentiation of effector-memory T cells. F1000Res 2018; 7: F1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6173108</ArticleId><ArticleId IdType="pubmed">30345004</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitard V, Roumanes D, Lafarge X, et al.. Long-term expansion of effector/memory Vdelta2-gammadelta T cells is a specific blood signature of CMV infection. Blood 2008; 112: 1317&#x2013;1324.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2515135</ArticleId><ArticleId IdType="pubmed">18539896</ArticleId></ArticleIdList></Reference><Reference><Citation>Pourgheysari B, Khan N, Best D, et al.. The cytomegalovirus-specific CD4+ T-cell response expands with age and markedly alters the CD4+ T-cell repertoire. J Virol 2007; 81: 7759&#x2013;7765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1933343</ArticleId><ArticleId IdType="pubmed">17409149</ArticleId></ArticleIdList></Reference><Reference><Citation>Aandahl EM, Quigley MF, Moretto WJ, et al.. Expansion of CD7(low) and CD7(negative) CD8 T-cell effector subsets in HIV-1 infection: correlation with antigenic load and reversion by antiretroviral treatment. Blood 2004; 104: 3672&#x2013;3678.</Citation><ArticleIdList><ArticleId IdType="pubmed">15308569</ArticleId></ArticleIdList></Reference><Reference><Citation>Champagne P, Ogg GS, King AS, et al.. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001; 410: 106&#x2013;111.</Citation><ArticleIdList><ArticleId IdType="pubmed">11242051</ArticleId></ArticleIdList></Reference><Reference><Citation>Paiardini M, Cervasi B, Albrecht H, et al.. Loss of CD127 expression defines an expansion of effector CD8+ T cells in HIV-infected individuals. J Immunol 2005; 174: 2900&#x2013;2909.</Citation><ArticleIdList><ArticleId IdType="pubmed">15728501</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor L, Urrea V, Carrillo J, et al.. Dynamics of CD4 and CD8 T-Cell subsets and inflammatory biomarkers during early and chronic HIV infection in mozambican adults. Front Immunol 2017; 8: 1925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5760549</ArticleId><ArticleId IdType="pubmed">29354131</ArticleId></ArticleIdList></Reference><Reference><Citation>Takata H, Kakazu JC, Mitchell JL, et al.. Long-term antiretroviral therapy initiated in acute HIV infection prevents residual dysfunction of HIV-specific CD8(+) T cells. EBioMedicine 2022; 84: 104253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9471490</ArticleId><ArticleId IdType="pubmed">36088683</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks SG.HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62: 141&#x2013;155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3759035</ArticleId><ArticleId IdType="pubmed">21090961</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks SG, Verdin E, McCune JM.Immunosenescence and HIV. Curr Opin Immunol 2012; 24: 501&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pubmed">22658763</ArticleId></ArticleIdList></Reference><Reference><Citation>Grosso TM, Alcami J, Arribas JR, et al.. HIV and aging, biological mechanisms, and therapies: what do we know? AIDS Rev 2022; 25: 79&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">35901108</ArticleId></ArticleIdList></Reference><Reference><Citation>Boppana S, Qin K, Files JK, et al.. SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence. PLoS Pathog 2021; 17: e1009761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8318272</ArticleId><ArticleId IdType="pubmed">34270631</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong F, Dai Y, Zheng T, et al.. Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals. J Clin Invest 2020; 130: 6588&#x2013;6599.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7685722</ArticleId><ArticleId IdType="pubmed">32841212</ArticleId></ArticleIdList></Reference><Reference><Citation>Juno JA, Tan HX, Lee WS, et al.. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat Med 2020; 26: 1428&#x2013;1434.</Citation><ArticleIdList><ArticleId IdType="pubmed">32661393</ArticleId></ArticleIdList></Reference><Reference><Citation>Ni L, Ye F, Cheng ML, et al.. Detection of SARS-CoV-2-Specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 2020; 52: 971.e3&#x2013;977.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196424</ArticleId><ArticleId IdType="pubmed">32413330</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentebibel SE, Lopez S, Obermoser G, et al.. Induction of ICOS+CXCR3+CXCR5+ TH cells correlates with antibody responses to influenza vaccination. Sci Transl Med 2013; 5: 176ra132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3621097</ArticleId><ArticleId IdType="pubmed">23486778</ArticleId></ArticleIdList></Reference><Reference><Citation>Chevalier N, Jarrossay D, Ho E, et al.. CXCR5 expressing human central memory CD4 T cells and their relevance for humoral immune responses. J Immunol 2011; 186: 5556&#x2013;5568.</Citation><ArticleIdList><ArticleId IdType="pubmed">21471443</ArticleId></ArticleIdList></Reference><Reference><Citation>Haltaufderhyde K, Srikiatkhachorn A, Green S, et al.. Activation of peripheral T follicular helper cells during acute dengue virus infection. J Infect Dis 2018; 218: 1675&#x2013;1685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6927865</ArticleId><ArticleId IdType="pubmed">29917084</ArticleId></ArticleIdList></Reference><Reference><Citation>He J, Tsai LM, Leong YA, et al.. Circulating precursor CCR7(lo)PD-1(hi) CXCR5(+) CD4(+) T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. Immunity 2013; 39: 770&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">24138884</ArticleId></ArticleIdList></Reference><Reference><Citation>Heit A, Schmitz F, Gerdts S, et al.. Vaccination establishes clonal relatives of germinal center T cells in the blood of humans. J Exp Med 2017; 214: 2139&#x2013;2152.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5502430</ArticleId><ArticleId IdType="pubmed">28637884</ArticleId></ArticleIdList></Reference><Reference><Citation>Locci M, Havenar-Daughton C, Landais E, et al.. Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 2013; 39: 758&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3996844</ArticleId><ArticleId IdType="pubmed">24035365</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikell I, Sather DN, Kalams SA, et al.. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog 2011; 7: e1001251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020924</ArticleId><ArticleId IdType="pubmed">21249232</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterrett S, Peng BJ, Burton RL, et al.. Peripheral CD4 T follicular cells induced by a conjugated pneumococcal vaccine correlate with enhanced opsonophagocytic antibody responses in younger individuals. Vaccine 2020; 38: 1778&#x2013;1786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8040292</ArticleId><ArticleId IdType="pubmed">31911030</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Bert N, Tan AT, Kunasegaran K, et al.. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 2020; 584: 457&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pubmed">32668444</ArticleId></ArticleIdList></Reference><Reference><Citation>Grobben M, van der Straten K, Brouwer PJ, et al.. Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. Elife 2021; 10: e70330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8610423</ArticleId><ArticleId IdType="pubmed">34812143</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Zhang L, Sang L, et al.. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest 2020; 130: 5235&#x2013;5244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7524490</ArticleId><ArticleId IdType="pubmed">32634129</ArticleId></ArticleIdList></Reference><Reference><Citation>Aydillo T, Gonzalez-Reiche AS, Aslam S, et al.. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med 2020; 383: 2586&#x2013;2588.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7722690</ArticleId><ArticleId IdType="pubmed">33259154</ArticleId></ArticleIdList></Reference><Reference><Citation>Fotouhi F, Salehi-Vaziri M, Farahmand B, et al.. Prolonged viral shedding and antibody persistence in patients with COVID-19. Microbes Infect 2021; 23: 104810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7963517</ArticleId><ArticleId IdType="pubmed">33741515</ArticleId></ArticleIdList></Reference><Reference><Citation>Long H, Zhao J, Zeng HL, et al.. Prolonged viral shedding of SARS-CoV-2 and related factors in symptomatic COVID-19 patients: a prospective study. BMC Infect Dis 2021; 21: 1282.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8711078</ArticleId><ArticleId IdType="pubmed">34961470</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou B, She J, Wang Y, et al.. Duration of viral shedding of discharged patients with severe COVID-19. Clin Infect Dis 2020; 71: 2240&#x2013;2242.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184358</ArticleId><ArticleId IdType="pubmed">32302000</ArticleId></ArticleIdList></Reference><Reference><Citation>Li N, Wang X, Lv T.Prolonged SARS-CoV-2 RNA shedding: not a rare phenomenon. J Med Virol 2020; 92: 2286&#x2013;2287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267144</ArticleId><ArticleId IdType="pubmed">32347980</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan D, Zhang X, Chen C, et al.. Characteristics of viral shedding time in SARS-CoV-2 Infections: a systematic review and meta-analysis. Front Public Health 2021; 9: 652842.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8017277</ArticleId><ArticleId IdType="pubmed">33816427</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Zhao B, Qu Y, et al.. Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically Ill patients with coronavirus disease 2019. Clin Infect Dis 2020; 71: 1937&#x2013;1942.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184354</ArticleId><ArticleId IdType="pubmed">32301997</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae S, Kim JY, Lim SY, et al.. Dynamics of viral shedding and symptoms in patients with asymptomatic or mild COVID-19. Viruses 2021; 13: 2133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8625453</ArticleId><ArticleId IdType="pubmed">34834940</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y.Long COVID after breakthrough SARS-CoV-2 infection. Nat Med 2022; 28: 1461&#x2013;1467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Asadi-Pooya AA, Akbari A, Emami A, et al.. Risk factors associated with long COVID syndrome: a retrospective study. Iran J Med Sci 2021; 46: 428&#x2013;436.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8611223</ArticleId><ArticleId IdType="pubmed">34840383</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai AD, Lavelle M, Boursiquot BC, et al.. Long-term complications of COVID-19. Am J Physiol Cell Physiol 2022; 322: C1&#x2013;C11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8721906</ArticleId><ArticleId IdType="pubmed">34817268</ArticleId></ArticleIdList></Reference><Reference><Citation>Montani D, Savale L, Noel N, et al.. Post-acute COVID-19 syndrome. Eur Respir Rev 2022; 31: 210185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8924706</ArticleId><ArticleId IdType="pubmed">35264409</ArticleId></ArticleIdList></Reference><Reference><Citation>Sneller MC, Liang CJ, Marques AR, et al.. A longitudinal study of COVID-19 sequelae and immunity: baseline findings. Ann Intern Med 2022; 175: 969&#x2013;979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9128805</ArticleId><ArticleId IdType="pubmed">35605238</ArticleId></ArticleIdList></Reference><Reference><Citation>Tleyjeh IM, Saddik B, AlSwaidan N, et al.. Prevalence and predictors of post-acute COVID-19 syndrome (PACS) after hospital discharge: a cohort study with 4 months median follow-up. PLoS One 2021; 16: e0260568.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8651136</ArticleId><ArticleId IdType="pubmed">34874962</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA 2020; 324: 1723&#x2013;1724.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8019677</ArticleId><ArticleId IdType="pubmed">33031513</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Madhavan MV, Sehgal K, et al.. Extrapulmonary manifestations of COVID-19. Nat Med 2020; 26: 1017&#x2013;1032.</Citation><ArticleIdList><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehandru S, Merad M.Pathological sequelae of long-haul COVID. Nat Immunol 2022; 23: 194&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127978</ArticleId><ArticleId IdType="pubmed">35105985</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavriatopoulou M, Korompoki E, Fotiou D, et al.. Organ-specific manifestations of COVID-19 infection. Clin Exp Med 2020; 20: 493&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7383117</ArticleId><ArticleId IdType="pubmed">32720223</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, et al.. Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review. J Infect Dis 2022; 226: 1593&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Jassat W, Abdool Karim SS, Mudara C, et al.. Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: a retrospective observational study. Lancet Glob Health 2022; 10: e961&#x2013;e969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9116895</ArticleId><ArticleId IdType="pubmed">35597249</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L, Rissmann M, Benavides FFW, et al.. In vitro and in vivo differences in neurovirulence between D614G, delta and omicron BA.1 SARS-CoV-2 variants. Acta Neuropathol Commun 2022; 10: 124.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9441226</ArticleId><ArticleId IdType="pubmed">36058935</ArticleId></ArticleIdList></Reference><Reference><Citation>Dan JM, Lindestam Arlehamn CS, Weiskopf D, et al.. A cytokine-independent approach to identify antigen-specific human germinal center T follicular helper cells and rare antigen-specific CD4+ T cells in blood. J Immunol 2016; 197: 983&#x2013;993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4955771</ArticleId><ArticleId IdType="pubmed">27342848</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiss S, Baxter AE, Cirelli KM, et al.. Comparative analysis of activation induced marker (AIM) assays for sensitive identification of antigen-specific CD4 T cells. PLoS One 2017; 12: e0186998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5655442</ArticleId><ArticleId IdType="pubmed">29065175</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Deitchman AN, Torres L, et al.. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep 2021; 36: 109518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8342976</ArticleId><ArticleId IdType="pubmed">34358460</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon MML, Rybkina K, Kato Y, et al.. SARS-CoV-2 infection generates tissue-localized immunological memory in humans. Sci Immunol 2021; 6: eabl9105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8626868</ArticleId><ArticleId IdType="pubmed">34618554</ArticleId></ArticleIdList></Reference><Reference><Citation>Visvabharathy L, Hanson B, Orban Z, et al.. Neuro-COVID long-haulers exhibit broad dysfunction in T cell memory generation and responses to vaccination. medRxiv. 2021.</Citation></Reference><Reference><Citation>Galan M, Vigon L, Fuertes D, et al.. Persistent overactive cytotoxic immune response in a spanish cohort of individuals with long-COVID: identification of diagnostic biomarkers. Front Immunol 2022; 13: 848886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8990790</ArticleId><ArticleId IdType="pubmed">35401523</ArticleId></ArticleIdList></Reference><Reference><Citation>Newell KL, Waickman AT.Inflammation, immunity, and antigen persistence in post-acute sequelae of SARS-CoV-2 infection Immunity and inflammation in post-acute sequelae of SARS-CoV-2 infection. Curr Opin Immunol 2022; 77: 102228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9127180</ArticleId><ArticleId IdType="pubmed">35724449</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Lu S, Tang AF, et al.. Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection. J Infect Dis 2021; 224: 1839&#x2013;1848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8643408</ArticleId><ArticleId IdType="pubmed">34677601</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB, et al.. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. Nat Immunol 2022; 23: 210&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan FJ, Hope CM, Masavuli MG, et al.. Long-term perturbation of the peripheral immune system months after SARS-CoV-2 infection. BMC Med 2022; 20: 26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8758383</ArticleId><ArticleId IdType="pubmed">35027067</ArticleId></ArticleIdList></Reference><Reference><Citation>Arunachalam PS, Wimmers F, Mok CKP, et al.. Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans. Science 2020; 369: 1210&#x2013;1220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665312</ArticleId><ArticleId IdType="pubmed">32788292</ArticleId></ArticleIdList></Reference><Reference><Citation>Filbin MR, Mehta A, Schneider AM, et al.. Longitudinal proteomic analysis of severe COVID-19 reveals survival-associated signatures, tissue-specific cell death, and cell-cell interactions. Cell Rep Med 2021; 2: 100287.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8091031</ArticleId><ArticleId IdType="pubmed">33969320</ArticleId></ArticleIdList></Reference><Reference><Citation>Gisby J, Clarke CL, Medjeral-Thomas N, et al.. Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death. Elife 2021; 10: e64827.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8064756</ArticleId><ArticleId IdType="pubmed">33704068</ArticleId></ArticleIdList></Reference><Reference><Citation>Thwaites RS, Sanchez Sevilla Uruchurtu A, Siggins MK, et al.. Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19. Sci Immunol 2021; 6: eabg9873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8128298</ArticleId><ArticleId IdType="pubmed">33692097</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Colon GJ, Ratnasiri K, Chen H, et al.. SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages. Sci Transl Med 2022: 14: eabm9151.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9529056</ArticleId><ArticleId IdType="pubmed">36137009</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheon IS, Li C, Son YM, et al.. Immune signatures underlying post-acute COVID-19 lung sequelae. Sci Immunol 2021; 6: eabk1741.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8763087</ArticleId><ArticleId IdType="pubmed">34591653</ArticleId></ArticleIdList></Reference><Reference><Citation>Montes-Ibarra M, Oliveira CLP, Orsso CE, et al.. The impact of long COVID-19 on muscle health. Clin Geriatr Med 2022; 38: 545&#x2013;557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8934728</ArticleId><ArticleId IdType="pubmed">35868672</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanderheiden A, Klein RS.Neuroinflammation and COVID-19. Curr Opin Neurobiol 2022; 76: 102608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9239981</ArticleId><ArticleId IdType="pubmed">35863101</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayakumar B, Boustani K, Ogger PP, et al.. Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease. Immunity 2022; 55: 542.e5&#x2013;556 e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8789571</ArticleId><ArticleId IdType="pubmed">35151371</ArticleId></ArticleIdList></Reference><Reference><Citation>Chopra V, Flanders SA, O&#x2019;Malley M, et al.. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med 2021; 174: 576&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7707210</ArticleId><ArticleId IdType="pubmed">33175566</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C, Huang L, Wang Y, et al.. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet 2021; 397: 220&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y, Tan C, Wu J, et al.. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res 2020; 21: 163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323373</ArticleId><ArticleId IdType="pubmed">32600344</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez R, Latorre A, Gonzalez-Jimenez P, et al.. Reduced diffusion capacity in COVID-19 survivors. Ann Am Thorac Soc 2021; 18: 1253&#x2013;1255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8328367</ArticleId><ArticleId IdType="pubmed">33472019</ArticleId></ArticleIdList></Reference><Reference><Citation>Mo X, Jian W, Su Z, et al.. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J 2020; 55: 2001217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7236826</ArticleId><ArticleId IdType="pubmed">32381497</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al.. Post-acute COVID-19 syndrome. Nat Med 2021; 27: 601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Liu X, Zhou Y, et al.. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med 2021; 9: 747&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8099316</ArticleId><ArticleId IdType="pubmed">33964245</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu YH, Dong JH, An WM, et al.. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J Infect 2020; 80: 394&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102535</ArticleId><ArticleId IdType="pubmed">32109443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao YM, Shang YM, Song WB, et al.. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine 2020; 25: 100463.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361108</ArticleId><ArticleId IdType="pubmed">32838236</ArticleId></ArticleIdList></Reference><Reference><Citation>Helms J, Kremer S, Merdji H, et al.. Neurologic features in severe SARS-CoV-2 infection. N Engl J Med 2020; 382: 2268&#x2013;2270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7179967</ArticleId><ArticleId IdType="pubmed">32294339</ArticleId></ArticleIdList></Reference><Reference><Citation>Heneka MT, Golenbock D, Latz E, et al.. Immediate and long-term consequences of COVID-19 infections for the development of neurological disease. Alzheimers Res Ther 2020; 12: 69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7271826</ArticleId><ArticleId IdType="pubmed">32498691</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou L, Zhang M, Wang J, et al.. Sars-Cov-2: underestimated damage to nervous system. Travel Med Infect Dis 2020; 36: 101642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269702</ArticleId><ArticleId IdType="pubmed">32220634</ArticleId></ArticleIdList></Reference><Reference><Citation>Apple AC, Oddi A, Peluso MJ, et al.. Risk factors and abnormal cerebrospinal fluid associate with cognitive symptoms after mild COVID-19. Ann Clin Transl Neurol 2022; 9: 221&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8862406</ArticleId><ArticleId IdType="pubmed">35043593</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniel C, Stein S, Ramelli S, et al.. SARS-CoV-2 infection and persistence throughout the human body and brain. Res Sq. Epub ahead of print 20 December 2021. DOI: 10.21203/rs.3.rs-1139035/v1.</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1139035/v1.</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C, Wang Z, Lorenzi JCC, et al.. Evolution of antibody immunity to SARS-CoV-2. Nature 2021; 591: 639&#x2013;644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Schultheiss C, Willscher E, Paschold L, et al.. The IL-1beta, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19. Cell Rep Med 2022; 3: 100663.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214726</ArticleId><ArticleId IdType="pubmed">35732153</ArticleId></ArticleIdList></Reference><Reference><Citation>Busatto GF, de Araujo AL, Castaldelli-Maia JM, et al.. Post-acute sequelae of SARS-CoV-2 infection: relationship of central nervous system manifestations with physical disability and systemic inflammation. Psychol Med 2022; 52: 2387&#x2013;2398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9151630</ArticleId><ArticleId IdType="pubmed">35521752</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang KC, Imig JD, Kalantar-Zadeh K, et al.. Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis. Curr Opin Nephrol Hypertens 2022; 31: 36&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">34846312</ArticleId></ArticleIdList></Reference><Reference><Citation>Maamar M, Artime A, Pariente E, et al.. Post-COVID-19 syndrome, low-grade inflammation and inflammatory markers: a cross-sectional study. Curr Med Res Opin 2022; 38: 901&#x2013;909.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935459</ArticleId><ArticleId IdType="pubmed">35166141</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis L, Perl A.Infection in systemic lupus erythematosus: friend or foe? Int J Clin Rheumtol 2010; 5: 59&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2830655</ArticleId><ArticleId IdType="pubmed">20209114</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivity S, Agmon-Levin N, Blank M, et al.. Infections and autoimmunity&#x2013;friends or foes? Trends Immunol 2009; 30: 409&#x2013;414.</Citation><ArticleIdList><ArticleId IdType="pubmed">19643667</ArticleId></ArticleIdList></Reference><Reference><Citation>Mawanda F, Wallace R.Can infections cause Alzheimer&#x2019;s disease? Epidemiol Rev 2013; 35: 161&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4707877</ArticleId><ArticleId IdType="pubmed">23349428</ArticleId></ArticleIdList></Reference><Reference><Citation>Piekut T, Hurla M, Banaszek N, et al.. Infectious agents and Alzheimer&#x2019;s disease. J Integr Neurosci 2022; 21: 73.</Citation><ArticleIdList><ArticleId IdType="pubmed">35364661</ArticleId></ArticleIdList></Reference><Reference><Citation>Soldan SS, Lieberman PM.Epstein-barr virus and multiple sclerosis. Nat Rev Microbiol 2022; 21: 51&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9362539</ArticleId><ArticleId IdType="pubmed">35931816</ArticleId></ArticleIdList></Reference><Reference><Citation>Nou E, Lo J, Grinspoon SK.Inflammation, immune activation, and cardiovascular disease in HIV. AIDS 2016; 30: 1495&#x2013;1509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4889507</ArticleId><ArticleId IdType="pubmed">27058351</ArticleId></ArticleIdList></Reference><Reference><Citation>Paiardini M, Muller-Trutwin M.HIV-associated chronic immune activation. Immunol Rev 2013; 254: 78&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3729961</ArticleId><ArticleId IdType="pubmed">23772616</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasa S, Fitch KV, Petrow E, et al.. Soluble CD163 is associated with shortened telomere length in HIV-infected patients. J Acquir Immune Defic Syndr 2014; 67: 414&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4213298</ArticleId><ArticleId IdType="pubmed">25197827</ArticleId></ArticleIdList></Reference><Reference><Citation>Maciel RA, Kluck HM, Durand M, et al.. Comorbidity is more common and occurs earlier in persons living with HIV than in HIV-uninfected matched controls, aged 50 years and older: a cross-sectional study. Int J Infect Dis 2018; 70: 30&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">29476902</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng X, Ouyang J, Isnard S, et al.. Sharing CD4+ T cell loss: when COVID-19 and HIV collide on immune system. Front Immunol 2020; 11: 596631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7770166</ArticleId><ArticleId IdType="pubmed">33384690</ArticleId></ArticleIdList></Reference><Reference><Citation>de Melo Silva J, Pinheiro-Silva R, Dhyani A, et al.. Cytomegalovirus and epstein-barr infections: prevalence and impact on patients with hematological diseases. Biomed Res Int 2020; 2020: 1627824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7605947</ArticleId><ArticleId IdType="pubmed">33163531</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer WA, Brown J, Wohl DA, et al.. Ebola virus ribonucleic acid detection in semen more than two years after resolution of acute ebola virus infection. Open Forum Infect Dis 2017; 4: ofx155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5897835</ArticleId><ArticleId IdType="pubmed">29670927</ArticleId></ArticleIdList></Reference><Reference><Citation>Keita AK, Vidal N, Toure A, et al.. A 40-month follow-up of Ebola virus disease survivors in guinea (PostEbogui) reveals long-term detection of Ebola viral ribonucleic acid in semen and breast milk. Open Forum Infect Dis 2019; 6: ofz482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7047953</ArticleId><ArticleId IdType="pubmed">32128327</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray K, Walker C, Herrington E, et al.. Persistent infection with West Nile virus years after initial infection. J Infect Dis 2010; 201: 2&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2791189</ArticleId><ArticleId IdType="pubmed">19961306</ArticleId></ArticleIdList></Reference><Reference><Citation>Group PIS, Sneller MC, Reilly C, et al.. A longitudinal study of Ebola sequelae in liberia. N Engl J Med 2019; 380: 924&#x2013;934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6478393</ArticleId><ArticleId IdType="pubmed">30855742</ArticleId></ArticleIdList></Reference><Reference><Citation>Carod-Artal FJ.Post-Ebolavirus disease syndrome: what do we know? Expert Rev Anti Infect Ther 2015; 13: 1185&#x2013;1187.</Citation><ArticleIdList><ArticleId IdType="pubmed">26293407</ArticleId></ArticleIdList></Reference><Reference><Citation>Hickie I, Davenport T, Wakefield D, et al.. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ 2006; 333: 575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1569956</ArticleId><ArticleId IdType="pubmed">16950834</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnus P, Gunnes N, Tveito K, et al.. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. Vaccine 2015; 33: 6173&#x2013;6177.</Citation><ArticleIdList><ArticleId IdType="pubmed">26475444</ArticleId></ArticleIdList></Reference><Reference><Citation>Morroy G, Keijmel SP, Delsing CE, et al.. Fatigue following acute Q-fever: a systematic literature review. PLoS One 2016; 11: e0155884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4880326</ArticleId><ArticleId IdType="pubmed">27223465</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas M, Monsalve DM, Pacheco Y, et al.. Ebola virus disease: an emerging and re-emerging viral threat. J Autoimmun 2020; 106: 102375.</Citation><ArticleIdList><ArticleId IdType="pubmed">31806422</ArticleId></ArticleIdList></Reference><Reference><Citation>de Melo GD, Lazarini F, Levallois S, et al.. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Sci Transl Med 2021; 13: eabf8396.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8158965</ArticleId><ArticleId IdType="pubmed">33941622</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandemirli SG, Altundag A, Yildirim D, et al.. Olfactory bulb MRI and paranasal sinus CT findings in persistent COVID-19 anosmia. Acad Radiol 2021; 28: 28&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7571972</ArticleId><ArticleId IdType="pubmed">33132007</ArticleId></ArticleIdList></Reference><Reference><Citation>Zollner A, Koch R, Jukic A, et al.. Postacute COVID-19 is characterized by gut viral antigen persistence in inflammatory bowel diseases. Gastroenterology 2022; 163: 495.e8&#x2013;506.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9057012</ArticleId><ArticleId IdType="pubmed">35508284</ArticleId></ArticleIdList></Reference><Reference><Citation>Group P-CC. Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med 2022; 10: 761&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Bevilacqua Filho CT, Schmidt AP, Felix EA, et al.. Risk factors for postoperative pulmonary complications and prolonged hospital stay in pulmonary resection patients: a retrospective study. Braz J Anesthesiol 2021; 71: 333&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9373437</ArticleId><ArticleId IdType="pubmed">34229858</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya B, Maung A, Barre K, et al.. Postoperative delirium is associated with increased intensive care unit and hospital length of stays after liver transplantation. J Surg Res 2017; 207: 223&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pubmed">27979481</ArticleId></ArticleIdList></Reference><Reference><Citation>Elfstrom KM, Hatefi D, Kilgo PD, et al.. What happens after discharge? An analysis of long-term survival in cardiac surgical patients requiring prolonged intensive care. J Card Surg 2012; 27: 13&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">22150640</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CC, Ho CH, Chen CM, et al.. Long-term risk of dementia after acute respiratory failure requiring intensive care unit admission. PLoS One 2017; 12: e0180914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5524355</ArticleId><ArticleId IdType="pubmed">28742105</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston DH, Tripp T, Biggs C, et al.. A fate worse than death? Long-term outcome of trauma patients admitted to the surgical intensive care unit. J Trauma 2009; 67: 341&#x2013;348; discussion 348&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pubmed">19667888</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahesh B, Choong CK, Goldsmith K, et al.. Prolonged stay in intensive care unit is a powerful predictor of adverse outcomes after cardiac operations. Ann Thorac Surg 2012; 94: 109&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pubmed">22579949</ArticleId></ArticleIdList></Reference><Reference><Citation>Unda SR, Labagnara K, Birnbaum J, et al.. Impact of hospital-acquired complications in long-term clinical outcomes after subarachnoid hemorrhage. Clin Neurol Neurosurg 2020; 194: 105945.</Citation><ArticleIdList><ArticleId IdType="pubmed">32480297</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams MR, Wellner RB, Hartnett EA, et al.. Long-term survival and quality of life in cardiac surgical patients with prolonged intensive care unit length of stay. Ann Thorac Surg 2002; 73: 1472&#x2013;1478.</Citation><ArticleIdList><ArticleId IdType="pubmed">12022535</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold JE, Okyay RA, Licht WE, et al.. Investigation of long COVID prevalence and its relationship to epstein-barr virus reactivation. Pathogens 2021; 10: 763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="pubmed">34204243</ArticleId></ArticleIdList></Reference><Reference><Citation>Alharbi KS, Singh Y, Hassan Almalki W, et al.. Gut microbiota disruption in COVID-19 or post-COVID illness association with severity biomarkers: a possible role of pre / pro-biotics in manipulating microflora. Chem Biol Interact 2022; 358: 109898.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8934739</ArticleId><ArticleId IdType="pubmed">35331679</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Mak JWY, Su Q, et al.. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. Gut 2022; 71: 544&#x2013;552.</Citation><ArticleIdList><ArticleId IdType="pubmed">35082169</ArticleId></ArticleIdList></Reference><Reference><Citation>Schult D, Reitmeier S, Koyumdzhieva P, et al.. Gut bacterial dysbiosis and instability is associated with the onset of complications and mortality in COVID-19. Gut Microbes 2022; 14: 2031840.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8855857</ArticleId><ArticleId IdType="pubmed">35174781</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Zhang J, Zhang D, et al.. Linking the gut microbiota to persistent symptoms in survivors of COVID-19 after discharge. J Microbiol 2021; 59: 941&#x2013;948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8356893</ArticleId><ArticleId IdType="pubmed">34382150</ArticleId></ArticleIdList></Reference><Reference><Citation>Crook H, Raza S, Nowell J, et al.. Long covid-mechanisms, risk factors, and management. BMJ 2021; 374: n1648.</Citation><ArticleIdList><ArticleId IdType="pubmed">34312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Yong SJ.Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond) 2021; 53: 737&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8146298</ArticleId><ArticleId IdType="pubmed">34024217</ArticleId></ArticleIdList></Reference><Reference><Citation>Salmon-Ceron D, Slama D, De Broucker T, et al.. Clinical, virological and imaging profile in patients with prolonged forms of COVID-19: a cross-sectional study. J Infect 2021; 82: e1&#x2013;e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833274</ArticleId><ArticleId IdType="pubmed">33285216</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeoh YK, Zuo T, Lui GC, et al.. Gut microbiota composition reflects disease severity and dysfunctional immune responses in patients with COVID-19. Gut 2021; 70: 698&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804842</ArticleId><ArticleId IdType="pubmed">33431578</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>